Journal
FUTURE ONCOLOGY
Volume 14, Issue 24, Pages 2543-2556Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0087
Keywords
alkaline phosphatase; biomarker; bone metastases; castration-resistant prostate cancer; mechanism of action; prognostic marker; survival
Categories
Funding
- Bayer
- Janssen-Cilag (Johnson Johnson)
- Merck Sharp Dohme
- Roche
- Bayer HealthCare Pharmaceuticals, LLC
- Takeda
- Astellas
- Daiichi-Sankyo
- Pfizer
- Taiho
- Nihon-Kayaku
- Endocyte
- Innocrin
- Johnson Johnson
- Sanofi-Aventis
- Bayer HealthCare Pharmaceuticals
Ask authors/readers for more resources
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available